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PD-L1 expression and its
clinicopathological correlation in advanced
esophageal squamous cell carcinoma in a
Chinese population
Lulu Rong1, Yong Liu2, Zhouguang Hui3, Zitong Zhao4, Yueming Zhang2, Bingzhi Wang1, Yanling Yuan1,
Wenbin Li1, Lei Guo1, Jianming Ying1, Yongmei Song4, Luhua Wang3, Zhongren Zhou5, Liyan Xue1,6* and
Ning Lu1*
Abstract
Background: Programmed death ligand 1 (PD-L1) is a ligand for the inhibitory programmed cell death protein 1 (PD-
1), which are targeted by several anti-PD-1 and PD-L1 drugs for a variety of human cancers. However, only a few
studies have evaluated PD-L1 expression in esophageal squamous cell carcinoma (ESCC) with a large Chinese cohort.
Our present study is to evaluate the association of PD-L1 expression with clinicopathological features on ESCC.
Methods: Using tissue microarray and immunohistochemistry, PD-L1 expression on tumor cells and tumor-infiltrating
immune cells was studied in 378 advanced ESCC patients without neoadjuvant chemoradiotherapy. Its correlation with
clinicopathological parameters was analyzed.
Results: PD-L1 was expressed on 29.9% (113/378) ESCC tumor cells and 40.2% (152/378) tumor-infiltrating immune
cells. PD-L1 expression in tumor cells was significantly correlated with age, degree of differentiation, T stage, N stage
and metachronous hematogenous metastasis, and PD-L1 expression in tumor-infiltrating immune cells was significantly
associated with N stage (P < 0.05). Patients with PD-L1 expression in tumor cells had poor disease-free survival (Hazard
ratio [HR] = 1.436, P = 0.009). There was a positive association between tumor cells and tumor-infiltrating immune cells for
PD-L1 expression (r = 0.16, P = 0.002). However, PD-L1 expression in tumor-infiltrating immune cells was not significantly
correlated with disease-free survival and overall survival.
Conclusions: PD-L1 expression in tumor cells and tumor infiltrating immune cells is not only an indicator for
immunotherapy, but also significantly related with age, differentiation, stage, metastasis and disease free survival.
Keywords: PD-L1, Esophageal squamous cell carcinoma, Clinicopathological parameters, Disease-free survival, Recurrence
Background
Esophageal squamous cell carcinoma (ESCC) is the 3rd
most common cause of death from cancer in China [1].
In spite of great progress of surgery and other treat-
ments, the prognosis of patients with advanced ESCC is
still very poor [2]. New therapies are urgently needed to
improve the survival rate and survival quality for ad-
vanced ESCC.
The immune checkpoint programmed cell death pro-
tein 1 (PD-1) is expressed in tumor-infiltrating immune
cells including T-lymphocytes, B-lymphocytes, natural
killer cells, monocytes, and dendritic cells. It is engaged
by the tumor expressed ligands including programmed
death ligand 1 (PD-L1) and PD-L2, which increases the
apoptosis of activated tumor-reactive T-cells and pro-
motes the growth of tumor cells in vivo [3]. Recently,
PD-L1 immune checkpoint inhibitor antibodies in mul-
tiple clinical trials were used to treat many cancer types
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[4–9], including melanoma, non-small cell lung cancer
(NSCLC), hepatocellular carcinoma, esophageal cancer
and bladder cancer.
In recent years, the relationship between PD-L1 expres-
sion and clinical outcomes have been studied in ESCC
[10–16]. However, the association of PD-L1 expression
with the clinicopathological relationship in ESCC remains
controversial. Some studies demonstrated that PD-L1 ex-
pression was correlated with poor prognosis [10, 17],
while some studies suggested that PD-L1 could be a favor-
able prognostic indicator in ESCC [12]. In one study,
PD-L1 expression was found to be not related to progno-
sis [18]. Our study aims to study the expression of PD-L1
in T2-T4a ESCC in a Chinese population and analyze its
correlation with clinicopathological parameters and prog-
nosis. These might provide a clue of the potential immune
based therapy strategy for ESCC patients.
Methods
Tissue samples
A total of 378 patients with primary esophageal squa-
mous cell carcinoma, who received radical esophagec-
tomy without neoadjuvant chemoradiotherapy in
National Cancer Center/National Clinical Research Cen-
ter for Cancer/Chinese Academy of Medical Sciences
and Peking Union Medical College between April 1999
and March 2003, were included in this retrospective
study. This study contained T2 stage (n = 103), T3 stage
(n = 238), T4a stage (n = 37), N1 stage (n = 116), N2 stage
(n = 52), and N3 stage (n = 21) cases. These cases were
non-consecutive cases which had complete follow-up
data. The patients’ medical records were reviewed to ob-
tain patients’ clinicopathological parameters, including
age at diagnosis, gender, tumor differentiation, tumor lo-
cation, vascular invasion, perineural invasion, metachro-
nous hematogenous metastasis, and pathological TNM
stage (Table 2). The HE slides were reviewed by two pa-
thologists (Lulu Rong and Liyan Xue) to obtain patho-
logical parameters, and any arguments were resolved by
consensus review. TNM staging according to the 8th
American Joint Committee on Cancer (AJCC) TNM
classification [19].
Tissue microarray construction
All tumor samples were fixed in 10% neutral buffered for-
malin for 12–48 h and embedded in paraffin. Tissue mi-
croarrays (TMAs) were constructed from three 0.6-mm
cores of tumor tissue and three 0.6-mm cores of normal
epithelium from each case using a Manual Tissue Arrayer
(MTA-1, Beecher Instruments, Silver Spring, MD).
Immunohistochemistry (IHC)
The IHC Envision staining method was used for immuno-
histochemical staining. Antigen retrieval was performed
by pressure oven 2.5 min in EDTA (pH 9.0). Slides
were incubated for 15 min with H2O2 (Dako,
Glostrup, Denmark). The primary antibody, rabbit
anti-PD-L1 monoclonal antibody (clone SP142; 1:50,
Spring Bioscience, Pleasanton, CA, USA) was incu-
bated sequentially for two hours at room temperature.
The bound antibody was then detected with the
horseradish peroxidase (HRP)-labeled goat anti-
mouse/rabbit secondary antibody (Dako, Glostrup,
Denmark) for 30 min at room temperature. Finally,
reaction products were visualized with 3, 3′-diamino-
benzidine (DAB, Dako, Glostrup, Denmark). Slides
were lightly counterstained with hematoxylin.
Evaluation of IHC
In our study, tumor cells and tumor-infiltrating immune
cells were quantified by evaluating the percentage of
stained and unstained cells (number of PD-L1-positive
tumor cells/number of all tumor cells or number of
PD-L1-positive tumor-infiltrating immune cells/number
of all tumor-infiltrating immune cells). The proportion
of PD-L1 positive expression in tumor cells was esti-
mated as different thresholds (< 1%, 1–9%, 10–49%, or ≥
50%) (Table 1), Tumor cells were designated PD-L1 posi-
tive expression when ≥1% of the tumor cells were posi-
tive for PD-L1, evaluated as partially or completely
staining on the cell membrane or cell membrane and
cytoplasm for tumor cells. Positive PD-L1 expression on
immune cells was defined as ≥1% positive cells with
membranous or cytoplasmic staining. Necrotic areas
were excluded from scoring. IHC results were evaluated
by two pathologists (Lulu Rong and Liyan Xue) in a
blinded manner. Doubtful cases were discussed by the
two pathologists using a multiheaded microscope until
consensus was achieved.
Statistical analysis
SPSS 19.0 software was used for statistical analysis. The
significance of the difference between PD-L1 expression
and clinicopathological parameters was assessed by the
univariate Logistic regression analysis. The relationship
between tumor cells and tumor-infiltrating immune cells
for PD-L1 expression was examined using correlation
analysis. Disease-free survival rates and overall survival
rates were calculated and survival curves were con-
structed using the Kaplan-Meier method, and the
log-rank test was used to evaluate the statistical
Table 1 PD-L1 expression based on the percent-positive tumor
cells by immunohistochemical staining
PD-L1 expression
in tumor cells (%)
< 1% 1–9% 10–49% ≥50%
Overall 265(70.1%) 51(13.5%) 34(9.0%) 28(7.4%)
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significance of differences. The prognostic significance
of clinicopathological parameters was determined using
univariate Cox proportional hazards analysis. To assess
the presence of possible confounding variables, the back-
ward stepwise multivariate Cox proportional hazards
analysis was applied for factors that achieved significance
in univariate Cox proportional hazards analysis. Hazard
ratios (HR) with 95% confidence intervals (CIs) were
reported.
All statistical tests were conducted as two-sided, and
P < 0.05 was considered to indicate a statistically signifi-
cant difference.
Results
PD-L1 expression in ESCC tumor cells and its correlation
with clinicopathological parameters
PD-L1 was found to be located on the cell membrane
and/or cytoplasm in ESCC tumor cells and tumor-infil-
trating immune cells (Fig. 1). The expression of PD-L1 in
ESCC tumor cells was positive in 29.9% (113/378), which
was associated with various clinicopathological
parameters including age, degree of differentiation, T
stage, N stage and metachronous hematogenous me-
tastasis. Poor differentiation ESCC had higher PD-L1
positive expression (Table 2).
PD-L1 expression in ESCC tumor-infiltrating immune cells
and its correlation with clinicopathological parameters
PD-L1 positive expression in ESCC tumor-infiltrating
immune cells was 40.2% (152/378) (Table 3). PD-L1
expression in tumor-infiltrating immune cells was sig-
nificantly associated with N stage (P < 0.05) (Table 3).
PD-L1 expression in tumor-infiltrating immune cells
was significantly associated with PD-L1 expression in
tumor cells (r = 0.16, P = 0.002; Table 4, Fig. 2).
Correlation between PD-L1 expression in ESCC tumor
cells and prognosis
The median disease-free survival time (DFS) was 41
months in PD-L1 negative patients and 18months in
PD-L1 positive patients, respectively. PD-L1 expression
was significantly associated with shorter DFS (P = 0.008).
Fig. 1 PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and adjacent non-malignant epithelium by immunohistochemistry staining.
a Strong positive expression of PD-L1 in tumor cells. Original magnification, 400×. b Weak positive expression of PD-L1 in tumor cells. Original
magnification, 400×. c Negative expression of PD-L1 in tumor cells. Original magnification, 400×. d The adjacent non-malignant epithelium. Original
magnification, 200×. e Positive expression of PD-L1 in tumor-infiltrating immune cells. Original magnification, 400×. f Negative expression of PD-L1 in
tumor-infiltrating immune cells. Original magnification, 400 ×
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The median overall survival time (OS) was 60 months
in PD-L1 negative patients and 36 months in PD-L1
positive patients, respectively. PD-L1 expression pa-
tients had a shorter OS, but not statistically signifi-
cant (P = 0.140) (Fig. 3). Univariate Cox analysis
showed that patients with PD-L1 expression had poor
DFS (Hazard ratio [HR] = 1.436, 95% CI: 1.095–1.883,
P = 0.009) (Table 5). However, multivariate Cox ana-
lysis failed to show PD-L1 as an independent prog-
nostic factor (Table 6).
Correlation between PD-L1 expression in ESCC tumor-
infiltrating immune cells and prognosis
The median DFS was 36months in PD-L1 positive
tumor-infiltrating immune cells patients and 34months
in PD-L1 negative patients, respectively. The median OS
was 53months in PD-L1 positive tumor-infiltrating im-
mune cells patients and 47months in PD-L1 negative
patients, respectively. No statistical significance was
found in both DFS and OS between PD-L1 positive and
negative tumor-infiltrating immune cell patients (median
Table 2 Relationships between clinicopathological characteristics and PD-L1 expression in tumor cells
Clinicopathological characteristics Overall PD-L1 (+) PD-L1 (−) Odds ratio (95% CI) Global P
378 113(29.9%) 265(70.1%)
Age at diagnosis 1.563(1.003–2.438) 0.049
≥ 60 years 188 65(34.6%) 123(65.4%)
< 60 years 190 48(25.3%) 142(74.7%)
Gender 0.800(0.461–1.386) 0.425
Male 307 89(29.0%) 218(71.0%)
Female 71 24(33.8%) 47(66.2%)
Tumor differentiation
Well 85 21(24.7%) 64(75.3%) 1
Moderate 190 51(26.8%) 139(73.2%) 1.118(0.621–2.013) 0.710
Poor 91 38(41.8%) 53(58.2%) 2.185(1.146–4.166) 0.018
Basaloid 12 3(25.0%) 9(75.0%) 1.016(0.251–4.105) 0.982
Location
Upper thoracic 61 18(29.5%) 43(70.5%) 1
Middle thoracic 209 59(28.2%) 150(71.8%) 0.940(0.502–1.759) 0.846
Lower thoracic 108 36(33.3%) 72(66.7%) 1.194(0.605–2.358) 0.609
PT status 1.821(1.068–3.106) 0.028
pT2 103 22(21.4%) 81(78.6%)
pT3-4a 275 91(33.1%) 184(66.9%)
PN status 1.541(1.210–1.963) < 0.001
pN0 189 40(21.2%) 149(78.8%)
pN1 116 43(37.1%) 73(62.9%)
pN2 52 20(38.5%) 32(61.5%)
pN3 21 10(47.6%) 11(52.4%)
Vascular invasion 1.025(0.656–1.600) 0.915
No 219 65(29.7%) 154(70.3%)
Yes 159 48(30.2%) 111(69.8%)
Perineural invasion 0.823(0.512–1.324) 0.422
No 253 79(31.2%) 174(68.8%)
Yes 125 34(27.2%) 91(72.8%)
Metachronous
hematogenous metastasis
2.030(1.171–3.520) 0.012
No 313 85(27.2%) 228(72.8%)
Yes 65 28(43.1%) 37(56.9%)
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OS, 53 versus 47months, P = 0.901; and median DFS, 36
versus 34months, P = 0.706).
Discussion
Our study is very unique compared to other reports since
we selected the ESCC esophagectomy samples without
neoadjuvant chemoradiotherapy, which excluded the pos-
sible treatment effect on PD-L1 expression. In the current
study, we found that 29.9% of T2-T4a ESCC cases were
positive for PD-L1 in tumor cells and 40.2% positive in
tumor-infiltrating immune cells. In addition, PD-L1 ex-
pression in ESCC tumor cells was associated with various
clinicopathological parameters including age, degree of
differentiation, stage, metastasis and DFS.
PD-L1 positive expression in ESCC tumor cells has been
reported in several studies from 18.9 to 45% [10–14]. Our
Table 3 Relationships between clinicopathological characteristics and PD-L1 expression in tumor-infiltrating immune cells
Clinicopathological characteristics Overall PD-L1 (+) PD-L1 (−) Odds ratio (95% CI) Global P
378 152(40.2%) 226(59.8%)
Age at diagnosis 0.853(0.565–1.288) 0.450
≥ 60 years 188 72(38.3%) 116(61.7%)
< 60 years 190 80(42.1%) 110(57.9%)
Gender 1.205(0.707–2.055) 0.494
Male 307 126(41.0%) 181(59.0%)
Female 71 26(36.6%) 45(63.4%)
Tumor differentiation
Well 85 32(37.6%) 53(62.4%) 1
Moderate 190 77(40.5%) 113(59.5%) 1.129(0.667–1.909) 0.652
Poor 91 37(40.7%) 54(59.3%) 1.135(0.619–2.081) 0.683
Basaloid 12 6(50.0%) 6(50.0%) 1.656(0.492–5.575) 0.415
Location
Upper thoracic 61 24(39.3%) 37(60.7%) 1
Middle thoracic 209 71(34.0%) 138(66.0%) 0.793(0.441–1.428) 0.440
Lower thoracic 108 57(52.8%) 51(47.2%) 1.723(0.911–3.260) 0.094
PT status 1.211(0.760–1.931) 0.421
pT2 103 38(36.9%) 65(63.1%)
pT3-4a 275 114(41.5%) 161(58.5%)
PN status 1.630(1.286–2.067) < 0.001
pN0 189 53(28.0%) 136(72.0%)
pN1 116 61(52.6%) 55(47.4%)
pN2 52 26(50.0%) 26(50.0%)
pN3 21 12(57.1%) 9(42.9%)
Vascular invasion 0.729(0.479–1.110) 0.141
No 219 95(43.4%) 124(56.6%)
Yes 159 57(35.8%) 102(64.2%)
Perineural invasion 0.939(0.606–1.455) 0.778
No 253 103(40.7%) 150(59.3%)
Yes 125 49(39.2%) 76(60.8%)
Metachronous hematogenous
metastasis
0.989(0.574–1.707) 0.969
No 313 126(40.3%) 187(59.7%)
Yes 65 26(40.0%) 39(60.0%)
Table 4 The relationship between tumor cells and tumor-infiltrating immune cells for PD-L1 expression
Variables Overall Tumor cells PD-L1(−) Tumor cells PD-L1(+) r P value
Tumor-infiltrating immune cells PD-L1(−) 226 172(76.1%) 54(23.9%) 0.160 0.002
Tumor-infiltrating immune cells PD-L1(+) 152 93(61.2%) 59(38.8%)
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current study showed that 29.9% of ESCC cases were
positive for PD-L1 in tumor cells. These differences
might be due to several factors including antibodies,
cut-off points, neoadjuvant therapy or IHC methods.
For example, Chen and his colleagues found that 45%
of ESCC tissues showed positive PD-L1 immunoreac-
tivity [10]. However, their study included neoadjuvant
chemoradiotherapy patients. Based on the data from
another study, Lim et al. found PD-L1 (5H1) expres-
sion increased in ESCC patients who received neoad-
juvant therapy [11]. Our present study excluded the
patients who had accepted neoadjuvant chemoradio-
therapy. In addition, Ito S et al. found that 18.9% of
ESCC tissues had positive PD-L1 (LS-B480) expres-
sion [13]. However, their study used the scoring for
PD-L1 expression based on adding both the propor-
tion score and the intensity score with cut-off as ≥7,
which is different from the current PD-L1 evaluation
guideline from clinical application. In our study, we
designated PD-L1 positive when ≥1% of the tumor
cells or immune cells were positive for PD-L1.
The association between PD-L1 expression and clini-
copathological features was reported in several studies.
The lymph node metastasis and tumor stages were
found to associate with PD-L1 expression in most
studies [10–13]. In our study, we had similar finding.
In addition, we also showed that PD-L1 expression
was associated with age and tumor differentiation.
We found the PD-L1 expression were significantly
higher in old patients (35%) than young patients
(25%). We also found that poor differentiation ESCC
had higher PD-L1 expression (42%) compared to well
(25%) and moderate (27%) differentiation groups. We
did not find that tumor location was associated with
A B
Fig. 2 PD-L1 expression in esophageal squamous cell carcinoma (ESCC) tumor cells and tumor-infiltrating immune cells. a PD-L1 positive expression in
tumor cells and tumor-infiltrating immune cells. Original magnification, 400×, (Black arrow shows the tumor-infiltrating immune cells). b PD-L1 negative
expression in tumor cells and tumor-infiltrating immune cells. Original magnification, 400×, (Black arrow shows the tumor-infiltrating immune cells)
Fig. 3 Kaplan-Meier curves of disease-free survival (DFS) and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) based upon
PD-L1 expression in tumor cells. a Patients with PD-L1 expression had significantly shorter DFS than those without PD-L1 expression (median DFS
time: 18 verse 41months, P = 0.008). b There was no statistically significant difference in OS between the patients with positive and negative
PD-L1 staining (median OS time: 36 verse 60 months, P = 0.140)
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PD-L1 expression, which was reported by Chen’s
study [10].
The association of PD-L1 expression with ESCC pa-
tient’s prognosis was controversial. Most of studies
found that PD-L1 expression was significantly related
with worse overall survival or disease free survival
[10, 11, 13–17, 20, 21]. However, a few studies re-
ported that PD-L1 positivity was associated with a fa-
vorable prognosis [12, 22, 23]. In our study, we found
that PD-L1 expression in tumor cells was significantly
correlated with DFS (41 months vs 18 months, PD-L1
negative vs positive) with univariate Cox analysis, but
multivariate Cox analysis failed to show PD-L1 as an
independent prognostic factor. In addition, we found
that the median OS was 60 months in PD-L1 negative
patients and 36 months in PD-L1 positive patients, re-
spectively. However, it was not statistically significant
(P = 0.140). Based on current data, PD-L1 expression
Table 5 Univariate COX analysis to determine factors associated with patient survival for PD-L1 expression in tumor cells
Variables Overall survival Disease-free survival
Hazard ratios 95%CI P value Hazard ratios 95%CI P value
PD-L1
Negative 1 1
Positive 1.240 0.929-1.653 0.144 1.436 1.095-1.883 0.009
Age
<60 years 1 1
≥60 years 1.303 0.995-1.705 0.054 1.205 0.932-1.557 0.154
Gender
Female 1 1
Male 1.033 0.737-1.448 0.849 0.942 0.684-1.297 0.714
Tumor differentiation
Well 1 1
Moderate 1.383 0.954-2.005 0.087 1.458 1.025-2.074 0.036
Poor 2.150 1.435-3.222 <0.001 2.180 1.478-3.216 <0.001
Basaloid 1.774 0.828-3.804 0.141 2.162 1.052-4.444 0.036
Location
Upper thoracic 1 1
Middle thoracic 0.872 0.602-1.262 0.468 0.960 0.669-1.379 0.826
Lower thoracic 0.798 0.529-1.204 0.282 0.900 0.604-1.341 0.604
PT status
pT2 1 1
pT3-4a 1.348 0.984-1.847 0.063 1.377 1.019-1.859 0.037
PN status
pN0 1 1
pN1 2.175 1.575-3.002 <0.001 2.277 1.681-3.084 <0.001
pN2 3.703 2.542-5.394 <0.001 3.291 2.284-4.744 <0.001
pN3 9.401 5.707-15.486 <0.001 8.029 4.875-13.225 <0.001
Vascular invasion
No 1 1
Yes 1.853 1.415-2.427 <0.001 1.714 1.326-2.218 <0.001
Perineural invasion
No 1 1
Yes 1.707 1.297-2.245 <0.001 1.645 1.267-2.138 <0.001
Metachronous hematogenous metastasis
No 1 1
Yes 2.533 1.868-3.435 <0.001 3.638 2.716-4.873 <0.001
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might be related with poorer prognosis, which might
be caused by the association of PD-L1 expression
with elder patients, lymph node metastasis, poor dif-
ferentiation and later stages.
Furthermore, we found the PD-L1 expression in ESCC
tumor-infiltrating immune cells was 40.2% (152/378).
PD-L1 expression in tumor-infiltrating immune cells
was significantly associated with N stage and PD-L1 ex-
pression in tumor cells. We analyzed the prognostic
relevance of PD-L1 expression in tumor-infiltrating im-
mune cells and showed that the median OS and DFS
were longer in patients with PD-L1 expression in
tumor-infiltrating immune cells, which was consistent
with recent study by Zhang et al. [18]. This might be an
indicator of a host immune response to tumor cells that
led to improve survival.
In addition, we also evaluated PD-L1 expression if the
cut-off point was 10% or 50%, based on the
percent-positive tumor cells by IHC, the PD-L1 positive
expression in tumor cells was 16.4 and 7.4%, respect-
ively. The positive expression of PD-L1 in ESCC tumor
cells was associated with tumor differentiation, T stage
and shorter DFS (Hazard ratio [HR] = 1.488, P = 0.017)
when the cut-off point was 10%, but not correlated with
OS (Hazard ratio [HR] = 1.255, P = 0.210), just as the re-
sult of the cut-off point was 1% (OS, Hazard ratio [HR]
= 1.240, P = 0.144; and DFS, Hazard ratio [HR] = 1.436,
P = 0.009). If the cut-off point was 50%, PD-L1 expres-
sion was just associated with age, but no significant as-
sociation was found between PD-L1 expression and the
prognosis (OS, Hazard ratio [HR] = 1.304, P = 0.293; and
DFS, Hazard ratio [HR] = 1.344, P = 0.218).
Table 6 Multivariate Cox analysis to determine independent factors associated with patient survival for PD-L1 expression in tumor cells
Variables Overall survival Disease-free survival
Hazard ratios 95%CI P value Hazard ratios 95%CI P value
PD-L1
Negative 1 1
Positive 0.882 0.648-1.200 0.423 1.047 0.782-1.401 0.758
Age
<60 years 1 1
≥60 years 1.623 1.223-2.152 0.001 1.442 1.109-1.875 0.006
Tumor differentiation
Well 1 1
Moderate 1.081 0.736-1.586 0.691 1.192 0.834-1.703 0.334
Poor 1.369 0.890-2.107 0.153 1.533 1.030-2.280 0.035
Basaloid 1.109 0.507-2.425 0.796 1.128 0.538-2.367 0.750
PT status
pT2 1 1
pT3-4a 1.119 0.800-1.565 0.512 1.295 0.945-1.776 0.108
PN status
pN0 1 1
pN1 2.054 1.485-2.841 <0.001 2.194 1.617-2.977 <0.001
pN2 3.316 2.242-4.906 <0.001 3.188 2.201-4.616 <0.001
pN3 8.016 4.726-13.749 <0.001 7.865 4.682-13.210 <0.001
Vascular invasion
No 1 1
Yes 1.291 0.970-1.718 0.080 1.103 0.831-1.464 0.497
Perineural invasion
No 1 1
Yes 1.328 0.999-1.764 0.051 1.325 1.012-1.736 0.041
Metachronous hematogenous metastasis
No 1 1
Yes 2.073 1.520-2.827 <0.001 3.359 2.499-4.517 <0.001
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PD-L1 positive expression in our data was relative
lower than the results from one meta-analysis [24]. The
lower PD-L1 expression in our TMA data might be
caused by tumor heterogeneity [25]. In order to reduce
the discordance of PD-L1 expression, TMAs in our
study were constructed from three cores of tumor tissue
and three cores of normal epithelium from each case.
One study showed that TMAs correlated moderately
well with that in the corresponding whole slide surgical
specimens [26].
To our knowledge, this is the first study that systemat-
ically analyzed the prognostic relevance of PD-L1 ex-
pression in tumor cells and tumor-infiltrating immune
cells in advanced ESCC patients who received radical
esophagectomy without neoadjuvant chemoradiotherapy.
ESCC patients with T2 or more advanced stages had
worse prognosis than T1 stage and were more likely to
be benefit from immunotherapy. The T1 stage ESCC pa-
tients had good prognosis, most of whom needed no ad-
juvant therapy after surgery, so we didn’t include the T1
stage ESCC patients in our study. However, our study
had some limitations. We examined PD-L1 expression
mainly in only sampled a small esophageal volume to
examine the prognostic value, which might result in
undersampling of esophageal cancer tissue and it was a
retrospective analysis of a population with different
stages from a single institution, the issue should be best
answered in context of a prospective study in a more pa-
tient population.
Conclusions
In conclusion, PD-L1 expression in ESCC is not only an in-
dicator for immunotherapy, but also is a potential prognos-
tic marker for untreated ESCC patients. PD-L1 expression
in both tumor cells and tumor-infiltrating immune cells is
significantly associated multiple clinicopathological features
including age, differentiation, stage and metastasis.
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